

# Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021

<https://marketpublishers.com/r/M0FC6CECDC94EN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: M0FC6CECDC94EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Methicillin-Resistant Staphylococcus Aureus Infections Understanding

#### Methicillin-Resistant Staphylococcus Aureus Infections: Overview

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens. The same organism that lives as a commensal and is transmitted in both health-care and community settings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and hospital-acquired infections. Genetically diverse, the epidemiology of MRSA is primarily characterized by the serial emergence of epidemic strains. Although its incidence has recently declined in some regions, MRSA still poses a formidable clinical threat, with

persistently high morbidity and mortality. Successful treatment remains challenging and requires the evaluation of both novel antimicrobials and adjunctive aspects of care, such as infectious disease consultation, echocardiography and source control.

'Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape is provided which includes the disease overview and Methicillin-Resistant Staphylococcus Aureus Infections treatment guidelines. The assessment part of the report embraces, in depth Methicillin-Resistant Staphylococcus Aureus Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Methicillin-Resistant Staphylococcus Aureus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Methicillin-Resistant Staphylococcus Aureus Infections R&D. The therapies under development are focused on novel approaches to treat/improve Methicillin-Resistant Staphylococcus Aureus Infections.

## Methicillin-Resistant Staphylococcus Aureus Infections Emerging Drugs Chapters

This segment of the Methicillin-Resistant Staphylococcus Aureus Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Methicillin-Resistant Staphylococcus Aureus Infections Emerging Drugs

TRL1068: Trellis Bioscience

TRL1068 is a high affinity mAb that targets the DNABII protein family; BLAST analysis has found hundreds of DNABII homologs across many bacterial species. TRL1068 is broad-spectrum, disrupting biofilm across multiple gram-positive and gram-negative bacteria species. Upon biofilm disruption, bacteria regain antibiotic susceptibility. The drug is currently in phase 1 of clinical trials for the treatment of patients with Methicillin-resistant *Staphylococcus aureus* infections.

#### Delpazolid (LCB01-0371): LegoChem Biosciences

Delpazolid (LCB01 0371) is an oxazolidinone derivative antibacterial therapeutic, being developed by LegoChem Biosciences Tuberculosis, Gram-positive infections; Methicillin-resistant *Staphylococcus aureus* infections; Vancomycin-resistant enterococcal infections.

Further product details are provided in the report

#### Methicillin-Resistant *Staphylococcus Aureus* Infections: Therapeutic Assessment

This segment of the report provides insights about the different Methicillin-Resistant *Staphylococcus Aureus* Infections drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Methicillin-Resistant *Staphylococcus Aureus* Infections

There are approx. 30+ key companies which are developing the therapies for Methicillin-Resistant *Staphylococcus Aureus* Infections. The companies which have their Methicillin-Resistant *Staphylococcus Aureus* Infections drug candidates in the most advanced stage, i.e. phase I include, Trellis Bioscience.

#### Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

#### Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## Methicillin-Resistant Staphylococcus Aureus Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Methicillin-Resistant Staphylococcus Aureus Infections therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Methicillin-Resistant Staphylococcus Aureus Infections drugs.

## Methicillin-Resistant Staphylococcus Aureus Infections Report Insights

### Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Analysis

### Therapeutic Assessment

### Unmet Needs

### Impact of Drugs

## Methicillin-Resistant Staphylococcus Aureus Infections Report Assessment

### Pipeline Product Profiles

### Therapeutic Assessment

### Pipeline Assessment

### Inactive drugs assessment

## Unmet Needs

### Key Questions

#### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Methicillin-Resistant Staphylococcus Aureus Infections drugs?

How many Methicillin-Resistant Staphylococcus Aureus Infections drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Methicillin-Resistant Staphylococcus Aureus Infections?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Methicillin-Resistant Staphylococcus Aureus Infections therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Methicillin-Resistant Staphylococcus Aureus Infections and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

Trellis Bioscience

LegoChem Biosciences

Aptorum Group

Allergan

iNtRON Biotechnology

Neupharma

ImmuPharma

Lytix Biopharma

CrystalGenomics

AIMM Therapeutics

Madam Therapeutics

ContraFect

Aphios

Cellics Therapeutics

GlaxoSmithKline

Kyorin Pharmaceuticals

Motif Bio

MicuRx

Oxford Antibiotic Group

Destiny Pharma

TSRL, Inc.

TAXIS Pharmaceuticals

Aridis Pharmaceuticals

Acurx Pharmaceuticals

Agile Biotics

Integrated BioTherapeutics

Biocidium Biopharmaceuticals Inc.

Azitra

## Key Products

TRL1068

Delpazolid

ALS 4

Dalbavancin

Tonabacase

Teicoplanin inhalation

Research programme: antibacterials

LTX 109

CG 400549

Research programme: anti-infective monoclonal antibodies

SAAP 148

Exebacase

Marinus



CTI 005

Gepotidacin

KRP-AM1977Y

Iclaprim

MRX 4

MRX 7

TetramOX

XF-73

TXA709

ARV-1801

AR-301

ACX-375C

ABX-605

IBT-V02

BCM-0184

## Contents

Introduction

Executive Summary

Methicillin-Resistant Staphylococcus Aureus Infections: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Methicillin-Resistant Staphylococcus Aureus Infections – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Methicillin-Resistant Staphylococcus Aureus Infections companies' collaborations, Licensing, Acquisition -Deal Value Trends

Methicillin-Resistant Staphylococcus Aureus Infections Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Tonabacase: iNtRON Biotechnology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

TRL1068: Trellis Bioscience

Product Description

Research and Development

Product Development Activities  
Drug profiles in the detailed report  
Inactive Products  
Comparative Analysis  
Methicillin-Resistant Staphylococcus Aureus Infections Key Companies  
Methicillin-Resistant Staphylococcus Aureus Infections Key Products  
Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs  
Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers  
Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and  
Conclusion  
Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views  
Methicillin-Resistant Staphylococcus Aureus Infections Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Methicillin-Resistant Staphylococcus Aureus Infections

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Methicillin-Resistant Staphylococcus Aureus Infections

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/M0FC6CECDC94EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M0FC6CECDC94EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970